Expression analysis of a panel of long non-coding RNAs (lncRNAs) revealed their potential as diagnostic biomarkers in bladder cancer

Abdolmaleki, Feraydoon; Ghafoui-Fard, Soudeh; Taheri, Mohammad; Mordadi, Alireza; Afsharpad, Mandana; Varmazyar, Sajad; Nazparvar, Bashir; Oskooei, Vahid Kholghi

doi:10.1016/j.ygeno.2019.04.020

Cited by 12 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25 Similar results were also reported in bladder cancer. 26 Interestingly, Wang et al found a significantly decreased risk of precancerous cervical lesions for the THRIL rs7133268 AG genotype (odds ratio adjusted=0.63). 27 These findings suggested the contentdependent role of THRIL during disease progression.…”

Section: Discussionmentioning

confidence: 98%

<p>Upregulated lncRNA THRIL/TNF-α Signals Promote Cell Growth and Predict Poor Clinical Outcomes of Osteosarcoma</p>

Xu¹,

Jin²,

Yang³

et al. 2020

OTT

View full text Add to dashboard Cite

Background: The immunosuppressive facet and tumorigenic role of TNF-α have been revealed in osteosarcoma (OS). Long noncoding RNA THRIL is identified to regulate TNF-α expression and participates in immune response. Thus, investigations on the clinical expression pattern of THRIL/TNF-α signal in OS would provide a potential target premise for OS patients. Methods: We collected OS (n=83), nontumor tissues (n=37) and serum samples (n=83 for OS and n=40 for healthy control) to determine the expressions and clinical significance of THRIL/TNF-α signal. Knockdown of THRIL in OS cell lines MG63 and Saos2 in vitro and in vivo was performed to confirm its function in the development of OS. Results: Elevated expression of THRIL was associated with increased TNF-α levels in OS tissues and serum samples. Combination of THRIL and TNF-α in tissues showed a more efficient diagnostic value for OS patients than either of them. Moreover, high-expressed THRIL was associated with larger tumor size, advanced Enneking stage and lung metastasis, whereas high TNF-α expression was found in patients with high histologic grade and patients who simultaneously harbor high THRIL and TNF-α showed the worst overall survival and metastasis-free survival. TNF-α signals increased OS cell vitalities in vitro but knockdown of THRIL inhibited TNF-α expressions, leading to impaired cell vitality, increased apoptosis and also downregulated epithelial to mesenchymal transition (EMT) phenotype and the ability of invasion, but these processes were restored by the treatment of TNF-α. The oncogenic role of THRIL/TNF-α signal was also confirmed in the xenograft model of MG63 cells. Conclusion: Overexpressed THRIL and TNF-α promoted OS progression with efficient diagnostic and prognostic value. THRIL/TNF-α signal supported cell growth and EMT phenotype of OS cells in vitro and in vivo.

show abstract

Section: Discussionmentioning

confidence: 98%

<p>Upregulated lncRNA THRIL/TNF-α Signals Promote Cell Growth and Predict Poor Clinical Outcomes of Osteosarcoma</p>

Xu¹,

Jin²,

Yang³

et al. 2020

OTT

View full text Add to dashboard Cite

show abstract

“…A single study in bladder cancer has reported similar levels of DSCAM-AS1 between tumoral and adjacent non-tumoral tissues ( Abdolmaleki et al, 2020 ). Other studies have in different types of cancer validated correlation between DSCAM-AS1 over-expression and low survival rate in terms of overall, disease-free or relapse free survival times.…”

Section: Clinical Investigationsmentioning

confidence: 98%

A Review on the Carcinogenic Roles of DSCAM-AS1

Ghafouri‐Fard

Khoshbakht

Taheri

et al. 2021

Front. Cell Dev. Biol.

Self Cite

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) are a group of transcripts with fundamental roles in the carcinogenesis. DSCAM Antisense RNA 1 (DSCAM−AS1) is an example of this group of transcripts which has been firstly identified in an attempt to find differentially expressed transcripts between breast tumor cells and benign breast samples. The pathogenic roles of DSCAM-AS1 have been vastly assessed in breast cancer, yet its roles are not restricted to this type of cancer. Independent studies in non-small cell lung cancer, colorectal cancer, osteosarcoma, hepatocellular carcinoma, melanoma and cervical cancer have validated participation of DSCAM-AS1 in the carcinogenic processes. miR-577, miR-122-5p, miR-204-5p, miR-136, miR−137, miR−382, miR−183, miR−99, miR-3173-5p, miR-874-3p, miR-874-3p, miR-150-5p, miR-2467-3p, miR-216b, miR-384, miR-186-5p, miR-338-3p, miR-877-5p and miR-101 are among miRNAs which interact with DSCAM-AS1. Moreover, this lncRNA has interactions with Wnt/β-catenin pathway. The current study aims at summarization of the results of studies which focused on the assessment of oncogenic role of DSCAM-AS1.

show abstract

“…Other panels, detecting urinary lncRNAs, such as UCA1-201, UCA1-203, MALAT1 or HOTAIR lncRNAs, yielded greater sensitivity and specificity (43.5–100% and 72–100%, respectively) than those targeting serum lncRNAs, but those too need further research and trials before taken in consideration for any further clinical application [ 122 , 123 , 124 , 125 , 126 , 127 , 128 , 129 ].…”

Section: Resultsmentioning

confidence: 99%

The Role of Novel Bladder Cancer Diagnostic and Surveillance Biomarkers—What Should a Urologist Really Know?

Malinaric

Mantica

Monaco

et al. 2022

IJERPH

View full text Add to dashboard Cite

The aim of this review is to analyze and describe the current landscape of bladder cancer diagnostic and surveillance biomarkers. We researched the literature from 2016 to November 2021 to find the most promising new molecules and divided them into seven different subgroups based on their function and location in the cell. Although cystoscopy and cytology are still the gold standard for diagnosis and surveillance when it comes to bladder cancer (BCa), their cost is quite a burden for national health systems worldwide. Currently, the research is focused on finding a biomarker that has high negative predictive value (NPV) and can exclude with a certainty the presence of the tumor, considering missing it could be disastrous for the patient. Every subgroup has its own advantages and disadvantages; for example, protein biomarkers cost less than genomic ones, but on the other hand, they seem to be less precise. We tried to simplify this complicated topic as much as possible in order to make it comprehensible to doctors and urologists that are not as familiar with it, as well as encourage them to actively participate in ongoing research.

show abstract

Expression analysis of a panel of long non-coding RNAs (lncRNAs) revealed their potential as diagnostic biomarkers in bladder cancer

Cited by 12 publications

References 14 publications

<p>Upregulated lncRNA THRIL/TNF-α Signals Promote Cell Growth and Predict Poor Clinical Outcomes of Osteosarcoma</p>

<p>Upregulated lncRNA THRIL/TNF-α Signals Promote Cell Growth and Predict Poor Clinical Outcomes of Osteosarcoma</p>

A Review on the Carcinogenic Roles of DSCAM-AS1

The Role of Novel Bladder Cancer Diagnostic and Surveillance Biomarkers—What Should a Urologist Really Know?

Contact Info

Product

Resources

About